BrightGene: Subsidiary BrightGene Pharmaceutical's product Dydrogesterone Tablets is expected to win the bid for national centralized drug procurement

Zhitong
2025.10.28 10:56

BrightGene announced that its wholly-owned subsidiary, BrightGene Pharmaceutical Co., Ltd., participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. BrightGene's product, Dydrogesterone Tablets, is expected to win the bid for this centralized procurement. Dydrogesterone Tablets received the drug registration certificate issued by the National Medical Products Administration in December 2024, making it a newly launched product for the company, generating sales revenue of 1.7351 million yuan from January to September 2025

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.